Palatin (PTN) Technologies announced the completion of enrollment in its Phase 2 Study of PL8177, a potent melanocortin-1 receptor agonist, in ulcerative colitis. The study is evaluating the safety, tolerability, efficacy, pharmacokinetics, and biomarkers of orally administered PL8177 in adult patients with active UC. The last patient visit is expected to occur in the first quarter of 2025, with topline data expected shortly thereafter.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PTN:
- Palatin Technologies Shifts Focus to Obesity Treatments
- Palatin to report data from MC4R selective PL7737 obesity program
- Palatin completes enrollment in Phase 2 study of bremelanotide in obesity
- Palatin’s melanocortin agonists shows efficacy in inflammatory diseases
- Palatin receives notice of non-compliance from NYSE American